Ironwood Pharmaceuticals (STU:I76) Interest Expense : €-25.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ironwood Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ironwood Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was € -6.3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-25.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ironwood Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was € 10.5 Mil. Ironwood Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was € -6.3 Mil. Ironwood Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 was 1.68. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ironwood Pharmaceuticals Interest Expense Historical Data

The historical data trend for Ironwood Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Interest Expense Chart

Ironwood Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-32.94

-24.23

-27.57

-7.17

-19.83

Ironwood Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.05	-1.24	-8.84	-8.84	-6.28

Ironwood Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-25.2 Mil.

Ironwood Pharmaceuticals (STU:I76) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ironwood Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was €-6.3 Mil. Its Operating Income for the three months ended in Mar. 2024 was €10.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €448.5 Mil.

Ironwood Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	10.54	/	-6.277
	=	1.68

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Ironwood Pharmaceuticals Inc interest coverage is 4.4, which is low.

Ironwood Pharmaceuticals (STU:I76) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (STU:I76) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

IRWD:USA I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ironwood Pharmaceuticals (STU:I76) Headlines

No Headlines